NewEdge Advisors’s SAB Biotherapeutics Warrant SABSW Stock Holding History

NewEdge Advisors’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,072	Closed	-$33	–	4355
2025 Q4	$33	Hold	1,072	–	–	﹤0.01%	4181
2025 Q3	$25	Hold	1,072	–	–	﹤0.01%	4068
2025 Q2	$35	Hold	1,072	–	–	﹤0.01%	3945
2025 Q1	$28	Hold	1,072	–	–	﹤0.01%	3877
2024 Q4	$80	Hold	1,072	–	–	﹤0.01%	3795
2024 Q3	$39	Hold	1,072	–	–	﹤0.01%	3753
2024 Q2	$50	Hold	1,072	–	–	﹤0.01%	3714
2024 Q1	$42	Hold	1,072	–	–	﹤0.01%	3741
2023 Q4	$32	Hold	1,072	–	–	﹤0.01%	3687
2023 Q3	$75	Hold	1,072	–	–	﹤0.01%	3378
2023 Q2	$112	Hold	1,072	–	–	﹤0.01%	3419
2023 Q1	$39	Hold	1,072	–	–	﹤0.01%	3368
2022 Q4	$0	Buy	+1,072	New	+$65	﹤0.01%	4184

Other funds holding SABSW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

NewEdge Advisors's SABSW Position: Q1 2026 in Review

NewEdge Advisors sold out of SAB Biotherapeutics Warrant (SABSW) in Q1 2026, closing a stake of 1,072 shares — an estimated $33 sold.

NewEdge Advisors first reported a position in SABSW in Q4 2022 and held it in 13 quarters. The position peaked at $112 in Q2 2023. 6 funds tracked by Wall St. Rank hold SABSW as of Q1 2026.

NewEdge Advisors reported no remaining SAB Biotherapeutics Warrant position as of Q1 2026 after selling out during the quarter.
NewEdge Advisors sold 1,072 SAB Biotherapeutics Warrant shares in Q1 2026, an estimated $33.
NewEdge Advisors first reported a position in SAB Biotherapeutics Warrant in Q4 2022 and held it in 13 quarters.
NewEdge Advisors's SAB Biotherapeutics Warrant position peaked at $112 in Q2 2023.
6 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.